The cross-border merger of BioAlliance Pharma and Topotarget is legally effective as of 22 July 2014 – Final calendar for trading on both Euronext and NASDAQ OMX to be available soon

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company specialized in the development of drugs in orphan oncology diseases, and Topotarget A/S (NASDAQ OMX Copenhagen – TOPO), announce that the cross-border merger between the two companies is legally effective as of 22 July 2014 to create Onxeo, dedicated to orphan oncology diseases.

BioAlliance Pharma, as the absorbing entity, will remain admitted to trading on Euronext Paris and will file for approval on the secondary trading and official listing on NASDAQ OMX Copenhagen. The final corresponding calendar will be announced shortly. The company will then operate under the name of Onxeo.

Onxeo will aim at becoming a global leader on the fast-growing market of orphan oncology drugs. It will hold a complementary portfolio of advanced programs targeting severe pathologies for which there is an unmet medical need. Onxeo will offer reinforced market attractiveness, notably towards specialized international investors, through a more important critical mass, a European scale and a portfolio of high added value products.

140723EN Onxeo – Merger Effectiveness Announcement